Corcept Therapeutics Incorporated (CORT)

Corcept Therapeutics Stock Forecast

Stock Price Forecast

The 4 analysts that cover Corcept Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $142, which forecasts a 99.33% increase in the stock price over the next year. The lowest target is $131 and the highest is $150.

Price Target: $142 (+99.33%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$131	$142	$145	$150
Change	+83.89%	+99.33%	+103.54%	+110.56%

* Price targets were last updated on May 6, 2025.

Analyst Ratings

The average analyst rating for Corcept Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '25	Feb '25	Mar '25	Apr '25	May '25	Jun '25
Strong Buy	3	3	3	3	3	3
Buy	1	1	1	1	1	1
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	4	4	4	4	4	4

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Swayampakula Ramakanth HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $150 → $145	Strong Buy	Maintains	$150 → $145	+103.54%	May 6, 2025
David Amsellem Piper Sandler	Piper Sandler	Buy Maintains $128 → $131	Buy	Maintains	$128 → $131	+83.89%	Apr 3, 2025
Edward Nash Canaccord Genuity	Canaccord Genuity	Strong Buy Maintains $130 → $142	Strong Buy	Maintains	$130 → $142	+99.33%	Apr 1, 2025
Joon Lee Truist Securities	Truist Securities	Strong Buy Maintains $76 → $150	Strong Buy	Maintains	$76 → $150	+110.56%	Mar 31, 2025
Swayampakula Ramakanth HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $115 → $150	Strong Buy	Maintains	$115 → $150	+110.56%	Mar 31, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

917.03M

Increased by 35.85%

from 675.04M

Revenue Next Year

1.24B

Increased by 35.22%

from 917.03M

EPS This Year

1.41

Increased by 14.23%

from 1.23

EPS Next Year

2.71

Increased by 93.10%

from 1.41

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	353.87M	365.98M	401.86M	482.38M	675.04M	917.03M	1.24B	1.64B
Revenue Growth	15.46%	3.42%	9.80%	20.04%	39.94%	35.85%	35.22%	32.42%
EPS	0.85	0.89	0.87	0.94	1.23	1.41	2.71	6.11
EPS Growth	10.39%	4.71%	-2.25%	8.05%	30.85%	14.23%	93.10%	125.06%
Forward PE	-	-	-	-	-	50.70	26.26	11.67
No. Analysts	-	-	-	-	-	6	6	5

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	946.4M	1.5B	2.1B
Avg	917.0M	1.2B	1.6B
Low	876.3M	1.0B	1.1B

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	40.2%	58.2%	69.4%
Avg	35.8%	35.2%	32.4%
Low	29.8%	10.2%	-10.3%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	1.60	4.16	7.70
Avg	1.41	2.71	6.11
Low	1.24	1.10	3.65

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	29.8%	195.9%	183.7%
Avg	14.2%	93.1%	125.1%
Low	1.2%	-21.9%	34.4%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.